
Biofidelity completes a successful study in collaboration with Agilent Technologies
Biofidelity has announced the successful completion of a study to detect key lung cancer mutations in collaboration with Agilent Technologies, a global leader in life sciences, diagnostics and applied chemicals.
The study showed an improvement in sensitivity of 50 times that achieved by current FDA approved methods.